Caelus Health recently started a key clinical trial in individuals suffering from Metabolic Syndrome or pre-diabetes; these individuals are at risk of developing Type 2 diabetes.
The microbiome product based on a single micro-organism (named A. soehngenii) may delay or even prevent the onset of diabetes. The trial is a final step in the development and registration of this product as a food supplement following successful completion of the previous study.
Caelus Health was established in close cooperation with Wageningen University.
Internist Max Nieuwdorp, of Amsterdam UMC, discovered a few years ago that the microorganisms in the intestines of many overweight people produce alcohol to an increased extent. Breaking down excessive alcohol leads to fatty liver disease, which in turn poses a risk of serious conditions such as diabetes and cardiovascular disease. Nieuwdorp has now received an ERC Advanced Grant of 2.5 million euros for a major study into the underlying causes of this excessive alcohol production.
NewsLaura Rupp has been awarded the Comenius Leadership Fellow grant for a three-year period. This grant of 500,000 Euros, will fund a project titled “Global English and International Dutch on the VU Campus”. Over the years, Rupp has successfully reached more than 100,000 people online worldwide, teaching how to understand diverse English accents and speak […]
NewsThe diagnosis of incurable cancer profoundly disrupts patients’ lives, often causing existential crises and a sense of lost purpose. The KWF-funded project “In Search of Stories” (ISOS) aimed to support these patients by partnering them with spiritual counsellors and professional artists. This co-creation process proved highly beneficial. New funding from KWF Dutch Cancer Society supports […]
News